Pharvaris N.V.
NASDAQ:PHVSBiotechnology
-$0.64 today
- Market cap
- $2.21B
- Beta
- -2.33
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$2.59
Volume 0.39M
Average 0.31M
PHVS Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Pharvaris N.V.NASDAQ: PHVS
Stock-Based Compensation · Q3 FY2026 · quarter ended Sep 2026
Stock-based compensation growth accelerates
Q3 FY2026 stock-based compensation of €6.81M rose 39.2% year over year, ahead of the -7.1% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 2.6% from the prior quarter. Over 3 fiscal years it compounded at +18.8% a year.
Context
- Stock-based compensation increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +39.2% holds above the trailing-twelve-month pace of -7.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
EUR · from the cash flow
- Latest · FY2025
- 19.05M EUR
- Year-over-year change
- +17.5%
- 4-year CAGR
- +23.5%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 19.05M | +17.5% |
| FY2024 | 2024-12-31 | 16.21M | +52.0% |
| FY2023 | 2023-12-31 | 10.66M | -6.0% |
| FY2022 | 2022-12-31 | 11.35M | +38.5% |
| FY2021 | 2021-12-31 | 8.2M | — |
Stock-Based Compensation vs competitors
How PHVS compares with its peers on the latest reported figures
- Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -7.1% is the 5th highest of 7, against a peer median of +60.5%.
- Over three fiscal years its annual growth of +18.8% compares with a peer median of +5.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $172.73B USD | +92559.3% | -2.6% | 16.8% | |
| LTM Jun 2026 | $121.89M USD | +50.0% | +23.9% | 13.0% | |
| LTM Sep 2026 | $72.84M USD | +70.9% | +5.6% | 11.2% | |
| LTM Jun 2026 | $49.78M USD | +71.5% | +62.2% | — | |
| LTM Sep 2026 | €17.97M EUR | -7.1% | +18.8% | — | |
| LTM Mar 2026 | $4.05M USD | -48.0% | -17.6% | 471.8% | |
| LTM Mar 2026 | $3.48M USD | -33.4% | — | 0.9% | |
| Peer median (excluding PHVS) | — | +60.5% | +5.6% | 13.0% | |
Competitors are the stored peer set for PHVS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (42.66M) | (75.65M) | (99.83M) | (132.4M) | (173.71M) |
| Depreciation & Amortization | 77.37K | 152.94K | 257.55K | 269.56K | 418.35K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 8.2M | 11.35M | 10.66M | 16.21M | 19.05M |
| Change in Working Capital | 1.58M | 8.38M | (5.86M) | 5.89M | 7.62M |
| Accounts Receivables | (130.5K) | 317.61K | (41.05K) | (34.32K) | (331.34K) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital | 1.71M | 8.06M | (5.82M) | 5.92M | 7.96M |
| Other Non-Cash Items | (11.79M) | (11.39M) | 1.72M | (10.1M) | 9.54M |
| Operating Cash Flow | (44.6M) | (67.16M) | (93.05M) | (120.13M) | (137.07M) |
| Capital Expenditures | (130.03K) | (124.3K) | (89.98K) | (538.09K) | (164.62K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (130.03K) | (124.3K) | (89.98K) | (538.09K) | (164.62K) |
| Debt Repayment | 0 | (119.53K) | (220.51K) | (159.66K) | (219.01K) |
| Common Stock Issued | 156.83M | 9.61M | 342.91M | 2.24M | 171.74M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (13.15M) | (839.97K) | (17.3M) | 592K | (10.91M) |
| Financing Cash Flow | 143.67M | 8.65M | 325.39M | 2.68M | 160.61M |
| Effect of Forex Changes | 11.78M | 11.12M | (2.86M) | 7.49M | (12.42M) |
| Net Change in Cash | 110.72M | (47.52M) | 229.39M | (110.5M) | 10.95M |
| Free Cash Flow | (44.73M) | (67.29M) | (93.14M) | (120.67M) | (137.24M) |
Pharvaris N.V.
NASDAQ:PHVS
Intrinsic Alpha fair value
Locked
Current Price
$31.55
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.